Novo Nordisk CEO: Still no capacity for large-scale M&A
NVO Novo Nordisk ADR
$44.28 -5.97%
차트·분석 보기 → - 1Novo Nordisk (NVO) CEO Doustdar reiterated on the Q2 earnings call that a large-scale, transformative acquisition remains distant
- 2The Bolt-on acquisition is being actively pursued, while Akero Therapeutics was acquired for $5.2 billion in October 2025
- 3With mixed pipeline clinical results and sluggish demand for the Wegovy pill, narrowing the gap with Eli Lilly (LLY) remains a difficult task
This 3-line summary is compiled from the report below.
The Wall Street Journal +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다